Eli Lilly and vs Moderna: Business Model & Financial Comparison 2026
Eli Lilly and · Healthcare / Drug Manufacturers - General·Moderna · Healthcare / Biotechnology
Financial Comparison
| Metric | LLYEli Lilly and | MRNAModerna |
|---|---|---|
| Market Cap | N/A | $21.88B |
| Revenue (TTM) | $72.25B | $2.23B |
| Revenue Growth | 55.5% | 2.1% |
| Gross Margin | 82.8% | -66.0% |
| Operating Margin | 49.4% | -557.9% |
| Net Margin | 35.0% | -141.4% |
| Return on Equity | 107.5% | -39.0% |
| P/E (Trailing) | 39.8x | N/A |
| P/E (Forward) | 24.9x | -11.4x |
| Free Cash Flow | $9.16B | $299.2M |
| Cash | $5.28B | $5.14B |
| Total Debt | $43.37B | $1.29B |
Data sourced from Yahoo Finance. Green highlights indicate better performance for that metric. Use the interactive tool for real-time data.
Business Model Comparison
Eli Lilly and
Eli Lilly and Company stands as a leading company in Healthcare. Generating $65.18 billion in annual revenue (growing 42.6% year-over-year) and carrying a market capitalization of $880.04 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Eli Lilly and Company continues to execute on a multi-year strategic vision that balances g…
Full Eli Lilly and analysis →Moderna
Moderna, Inc. stands as a leading company in Healthcare. Generating $1.94 billion in annual revenue (growing -29.8% year-over-year) and carrying a market capitalization of $21.26 billion, the company has cemented its position as a foundational player in the global Biotechnology landscape. Under the leadership of its leadership team, Moderna, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholde…
Full Moderna analysis →SWOT Analysis Comparison
Strengths
Eli Lilly and
- With a market capitalization of $880.04B, Eli Lilly and Company is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital acces
- Eli Lilly and Company's gross margin of 83.0% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 44.9% demonstrates
- Revenue grew 42.6% year-over-year to $65.18B, indicating strong demand for Eli Lilly and Company's products and services and outperformance relative to many industry peers.
Moderna
- Moderna, Inc. holds an established position in the Biotechnology sector, with a track record of serving customers and generating value across its core business activities.
- The company's deep expertise in Biotechnology — developed over years of operation — provides meaningful barriers to entry and customer relationship advantages that newer competitors must overcome.
Weaknesses
Eli Lilly and
- With a debt-to-equity ratio of 165.3, Eli Lilly and Company carries significant debt relative to equity. While manageable given its cash flow, elevated leverage limits financial flexibility and increa
Moderna
- Year-over-year revenue declined 29.8%, raising questions about demand for Moderna, Inc.'s core offerings and requiring management to articulate a credible recovery path.
Opportunities
Eli Lilly and
- Eli Lilly and Company operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains i
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Eli Lil
- Earnings growth of 51.4% YoY demonstrates Eli Lilly and Company's ability to convert revenue growth into shareholder value. Analysts project continued earnings expansion driven by operating leverage a
Moderna
- Moderna, Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment tran
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Moderna
- With $5.80B in cash and strong free cash flow generation, Moderna, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.
Threats
Eli Lilly and
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Eli Lilly and Company's revenue is not fully insulated from macroeconomic cycles, and a rece
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Eli Lilly and Compa
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Moderna
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Moderna, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession sc
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Moderna, Inc.'s bus
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Compare any 2–4 companies with live data
The interactive comparison tool lets you select any companies, see real-time metrics, and export a side-by-side report.
Open Comparison ToolEli Lilly and vs Moderna: FAQ
- Is Eli Lilly and bigger than Moderna?
- Both companies are significant players in their respective markets. See the financial comparison table above for current market capitalization data.
- Which has better profit margins — Eli Lilly and or Moderna?
- Eli Lilly and has higher net profit margins (35.0%) compared to Moderna (-141.4%). Gross and operating margins are compared in the table above.
- What sectors do Eli Lilly and and Moderna operate in?
- Eli Lilly and operates in the Healthcare sector (Drug Manufacturers - General). Moderna operates in the Healthcare sector (Biotechnology).
- How does Eli Lilly and's revenue compare to Moderna's?
- Eli Lilly and generates $72.25B in annual revenue (TTM) while Moderna generates $2.23B. Eli Lilly and is the larger company by revenue as of 2026.